Zaranta

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zaranta

Quick Facts: Zaranta (Rosuvastatin)

Property Description
Active ingredient Rosuvastatin Calcium
Form Oral tablet (Film-coated)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Management of high cholesterol and related lipid disorders
Origin Synthetic, single-ingredient compound

What Type of Medicine is Zaranta (Rosuvastatin)?

Zaranta is an oral tablet containing the single active substance Rosuvastatin (INN), a synthetic compound classified as an HMG-CoA Reductase Inhibitor, which is the formal name for the class of medicines commonly known as statins. The medicine is supplied as a film-coated oral tablet and functions as a single-ingredient product. Rosuvastatin is a hydrophilic statin, meaning it is more water-soluble, which is a property that contributes to its enhanced selective uptake by liver cells where its action is required. This characteristic hepatoselectivity of Rosuvastatin facilitates its targeted activity in the liver. The primary purpose of the medicine is to intervene in the body’s internal cholesterol production process by competitively inhibiting the enzyme HMG-CoA reductase.

General Purpose and Action of Zaranta

The fundamental purpose of Zaranta is to serve as a potent lipid-lowering agent to achieve systemic management of abnormal levels of circulating fatty substances in the blood, broadly known as dyslipidemia. By slowing the production of endogenous cholesterol within the liver, the medicine triggers an increased expression of hepatic receptors that actively clear cholesterol from the bloodstream. This leads to a systematic reduction in the concentration of detrimental particles, specifically Low-Density Lipoprotein Cholesterol (LDL-C) and Very Low-Density Lipoprotein (VLDL). The medicine acts to decrease "bad cholesterol" and triglycerides. A typical neutral use scenario for a medicine of this class is the long-term management required for adults and adolescents with high cholesterol to help maintain healthy lipid profiles. The overall effect provides a robust foundation for the therapeutic management of lipid imbalances.

Regulatory References

  1. NIH StatPearls: Rosuvastatin Class

What side effects are possible with Zaranta?

Possible Side Effects and Safety Information

Regulatory agencies have issued prominent warnings regarding the use of medicines in the Janus Kinase (JAK) inhibitor class, to which Zaranta belongs. These official warnings concern an increased risk of several serious adverse events compared to other biologic therapies.

Serious and Clinically Significant Adverse Reactions

The most serious risks that require a high-level regulatory alert include:

  • Serious Heart-Related Events: Increased risk of major adverse cardiovascular events (MACE), including heart attack (myocardial infarction) and stroke.
  • Malignancy (Cancer): Increased risk of certain cancers, including lymphoma and lung cancer. Periodic skin examination may be recommended for patients with an increased risk of skin cancer.
  • Thrombosis (Blood Clots): Increased risk of developing blood clots in deep veins (DVT), in the lungs (pulmonary embolism or PE), and in arteries.
  • Serious Infections and Mortality: Increased risk of serious infections and death from any cause compared to an older class of drugs (TNF blockers).

Other adverse events commonly reported in clinical trials for this drug class include upper respiratory tract infections, headache, cough, and increased cholesterol and blood pressure levels.

Safety Restrictions and Monitoring

Population-Specific Considerations: The drug should generally be reserved for use only when no suitable alternative treatments are available for patients who are 65 years of age or older, those who are current or past long-time smokers, or those with existing cardiovascular or malignancy risk factors. Doses may need to be adjusted in certain patient groups to mitigate risks of blood clots.

Regulatory Limitations: Health authorities limit the use of this drug class to patients who have had an inadequate response or intolerance to other types of treatment. The risks and benefits must be carefully evaluated for each patient before initiating therapy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Zaranta (Rosuvastatin)


Overdose Scope

Entity Official Regulatory Statement
Documented overdose presentations: No specific symptoms or characteristic clinical manifestations have been formally documented in the Overdosage section of the regulatory labels following a single acute overdose.
Physiological systems affected (as stated in label): Skeletal muscle (potential for Myopathy and Rhabdomyolysis); Renal system (potential for Acute Renal Failure secondary to myoglobinuria).
Dose-related or exposure-related factors (if applicable): Severe complications like rhabdomyolysis are associated with high exposures or concurrent risk factors.
Population-specific overdose notes (if applicable): No specific manifestations for overdose in pediatric or geriatric populations are listed in the Overdosage section.
Emergency-response statements (as written in official documents): Treatment in the event of overdosage should be symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention for any suspected overdose event.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): Not specifically categorized as mild, moderate, or severe in acute overdose, but potential complications are classified as serious.
Regulatory basis (EMA / FDA / etc.): Primarily based on EMA SmPC and FDA Prescribing Information.
Overdose-context constraints (as defined in official documents): The official guidance states that no specific antidote is known and that hemodialysis is not anticipated to be of benefit.

Resulting Overdose Structure

Official Overdose Statements:

  • No specific symptoms are known following an acute overdose event, according to regulatory documentation.
  • In the event of overdosage, there is no specific treatment or antidote documented.
  • Treatment must be symptomatic and supportive, and hemodialysis is not anticipated to be of benefit.
  • Continuous monitoring of the patient is required, including the assessment of Creatine Kinase (CK) levels and Liver Function Tests (LFTs), reflecting the primary risks.
  • It is mandatory to seek immediate medical attention for any suspected overdose.

Connection to the Overall Overdose Profile

Governmental regulatory documents define the rosuvastatin overdose profile by emphasizing the lack of a characteristic symptom profile and the need for symptomatic and supportive treatment. Since specific acute overdose manifestations are not listed, the profile mandates an immediate emergency response to ensure continuous monitoring and management of the potential severe, documented risks associated with the drug class, such as rhabdomyolysis and subsequent acute renal failure. The official guidance is strictly limited to these supportive actions, as no specific antidote is known.

Therapeutic Uses of Zaranta

Zaranta (Rosuvastatin) is commonly used across conditions characterized by periods of heightened symptoms involving lipid disorders. Its main purpose is to manage conditions associated with systemic imbalance and may assist with addressing risks associated with cardiovascular functional stress in adults. The therapeutic domain for its active ingredient, rosuvastatin, includes managing conditions such as hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia. It is also considered relevant in contexts involving heightened systemic burden related to cardiovascular concerns in certain patient groups.


Zaranta belongs to the category of medicines called statins. It is applied in addressing conditions associated with systemic imbalance, such as high cholesterol, which create noticeable functional strain. This symptomatic support contributes to improved comfort during periods of heightened symptoms and helps maintain a sense of stability when symptoms related to systemic imbalance are noticeable. The medication supports general well-being during symptomatic phases and is commonly used to help with conditions characterized by periods of heightened symptoms. It assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: May assist with symptoms related to systemic imbalance

Eligibility and Restrictions for Use

This section outlines the official eligibility requirements and exclusions for Zaranta as defined in authoritative government regulatory documents.

Contraindicated Populations and Conditions

The medicine must not be used in patients who have a known hypersensitivity to the active substance or to any component of the formulation. Additionally, use is strictly contraindicated in patients with active liver disease, including those with unexplained, persistent elevations of serum transaminases.

Physiological and Age Restrictions

Population Group Eligibility Status (as per official label)
Pregnancy Contraindicated (May cause fetal harm)
Lactation Not recommended (Drug is excreted in human milk)
Pediatric Use Use in patients below a certain age (e.g., 6 or 8 years) is often not established

Condition-Specific Eligibility Rules

Eligibility is limited by organ function. The medicine is contraindicated in patients with severe renal impairment (e.g., creatinine clearance less than 30 mL/min). Treatment is also not recommended in patients with moderate or severe liver dysfunction. Use is only permitted in adults who do not have these exclusions, and caution is advised for older adults who may have predisposing risk factors.

What should I know about interactions with other medicines?

Zaranta’s interaction profile is defined by official regulatory documentation, focusing on effects that modify systemic exposure and increase the risk of muscle toxicity. Co-administration with Cyclosporine is officially contraindicated due to a significant, documented increase in rosuvastatin plasma concentrations.

Pharmacokinetic and Exposure Interactions

Rosuvastatin is a substrate for the drug transporters OATP1B1 and BCRP. Inhibitors of these transporters, including certain antiviral medicines (such as Lopinavir/Ritonavir) and other medicines like Darolutamide and Regorafenib, are officially noted to raise rosuvastatin's systemic exposure (AUC/Cmax). This requires mandated dose limitations for rosuvastatin when co-administered. Aluminum and Magnesium Hydroxide Antacids reduce rosuvastatin absorption and must be administered at least 2 hours before rosuvastatin.

Pharmacodynamic and Risk Interactions

Pharmacodynamically, co-administration with fibrates (like Gemfibrozil) or Colchicine increases the officially recognized risk of myopathy and rhabdomyolysis. Use with lipid-modifying doses of niacin (ge 1 g/day) also increases this muscle risk. Anticoagulants like Warfarin can have their effect prolonged, requiring frequent International Normalized Ratio (INR) monitoring. The 40 mg dose is formally contraindicated in Asian patients and those with moderate renal impairment due to observed increases in systemic exposure in these groups.

Mechanism of Action

Zaranta (Rosuvastatin) operates exclusively at the biological and physiological level by engaging three primary mechanistic domains: enzyme inhibition, receptor upregulation, and non-lipid pathway modulation.


Central Mechanism: Blocking the Body's Cholesterol Factory

The primary mechanism involves the competitive and reversible inhibition of the enzyme HMG-CoA Reductase (HMGCR) . HMGCR is the rate-limiting step for hepatic cholesterol biosynthesis (the mevalonate pathway). By blocking this enzyme, the medicine reduces the internal supply of cholesterol within liver cells, initiating the subsequent cascade of lipid clearance.


Systemic Effect: Activating Circulating Lipid Clearance

The resulting intracellular cholesterol deficit triggers a critical physiological response: the upregulation of Low-Density Lipoprotein (LDL) Receptors on the surface of liver cells. These newly expressed receptors actively and rapidly bind and remove atherogenic lipoproteins, such as LDL-C and VLDL, from the bloodstream, resulting in a systemic reduction in plasma lipid levels.


Complementary Action: Modulating Vascular Signals

Beyond modifying lipid levels, the mechanism also exerts pleiotropic effects by reducing the downstream synthesis of specific signaling molecules (isoprenoids) required for vascular cell function. This action modulates pathways involved in endothelial function and subclinical inflammation.

Dosage and Administration Information

How to Use Zaranta (Rosuvastatin): Administration Guidelines

Zaranta is consistently administered as an oral film-coated tablet, available in strengths of 5 mg, 10 mg, 20 mg, and 40 mg. The usage pattern is once daily, and the tablet must be swallowed whole at any time of day, with or without food.


Standard Dosing and Schedule

The standard adult starting dose is typically 10 mg or 20 mg daily. A lower 5 mg starting dose may be applied for patients who may be predisposed to elevated systemic exposure, including those of Asian ancestry and older adults.

The overall maintenance range is 5 mg to the maximum daily dosage of 40 mg. The 40 mg dose is not intended for routine initiation but is reserved only for individuals who have not reached their treatment goals on the 20 mg dose. Dose adjustments are a procedural step, typically occurring at intervals of 2 to 4 weeks following the start of therapy or a previous dose change.

Special Administrative Conditions

Condition Guideline
Severe Renal Impairment Starting dose of 5 mg daily; should not exceed 10 mg daily.
Missed Dose Skip the missed dose and resume with the next scheduled daily dose. Do not take an extra dose.
Administration Route Oral only; tablet must be swallowed whole

This medication is intended for long-term management, and the instructions establish a continuous use protocol centered on flexible daily timing and dosage caps for certain patient groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zaranta (Rosuvastatin)


Evidence for Use in Managing High Cholesterol (Primary and Mixed Dyslipidemia)

Research has explored the use of Zaranta in individuals with high cholesterol, a context involving outcomes related to systemic or functional imbalance. Research in this area primarily involves short-term, randomized controlled trials (RCTs), where study participants were closely monitored over defined time intervals, often ranging from a few weeks up to one year. These trials compared the use of Zaranta against a placebo or an active comparator.

What studies monitored were changes in key blood biomarkers, specifically the levels of Low-Density Lipoprotein Cholesterol (LDL-C, or "bad cholesterol"), Total Cholesterol, and Triglycerides. Studies reported measurable changes in these biomarkers were observed in the adult populations who were studied. Research provides insight into how lipid levels evolved during the study period, as a primary focus was on whether study participants achieved specific predefined target levels for these blood fats.


Evidence for Cardiovascular Event Occurrence

Research was studied for the occurrence of major cardiovascular events in large-scale, long-term randomized trials, which are different from the shorter cholesterol-level studies. These trials enrolled adults both with and without clinically evident heart conditions who had other associated risk factors. These long-term trials monitored the frequency of major cardiovascular events, such as nonfatal heart attacks, nonfatal strokes, and cardiovascular-related death, in contexts involving physiological strain or stress.

Findings indicate patterns related to MACE frequency in the observed populations with varying risk levels. This type of long-term evidence contributes to the broader evidence landscape by tracking major clinical endpoints rather than just blood fat biomarkers. Furthermore, some research has explored changes in inflammatory biomarkers like high-sensitivity C-reactive protein (hsCRP) in specific populations.


Remaining Research Gaps and Uncertainties

Despite the extensive research conducted, certain areas remain uncertain or require further exploration to provide a complete context. Direct, head-to-head evidence tracking major cardiovascular events between Zaranta and many similar medicines comparative evidence is lacking for certain comparisons.

Furthermore, data for certain groups remain insufficient, particularly for patients with multiple complex or rare medical conditions, meaning that the results apply only to the populations studied and do not easily generalize to every possible patient profile. Finally, the evidence quality varies across studies, and many initial findings need continuous confirmation through ongoing real-world evidence programs and additional long-term trials, as the long-term effects are not fully established for all populations over decades of use.

Key Studies & References

  1. Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) Trial
  2. An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia (Referencing ClinicalTrials.gov NCT01078675)

Frequently Asked Questions (FAQ)

Common questions about Zaranta (FAQ)


Q: How quickly does Zaranta start working?

Regulatory documents indicate that Zaranta begins to affect blood cholesterol levels soon after starting treatment. The full, maximum reduction in 'bad cholesterol' (LDL-C) is generally observed within two to four weeks following the start of therapy or after a dose change.


Q: How long do the effects of Zaranta last?

Zaranta is intended for long-term management of high cholesterol. The official product information states that the cholesterol-lowering effects require continuous, daily use to be sustained. If treatment is stopped, cholesterol levels will typically rise and return to pre-treatment levels.


Q: Is Zaranta considered a high-risk medication?

Official documentation includes a Warnings and Precautions section to highlight potential serious adverse effects. These include possible muscle damage (myopathy) and liver enzyme abnormalities. These risks are a central focus of monitoring for those using the medicine.


Q: Is Zaranta safe for elderly patients?

Regulatory documents describe conditions for use in the elderly, noting that a lower starting dose (such as 5 mg) may be indicated. Advanced age (65 years or greater) is noted as a potential risk factor for myopathy. Official information indicates the need for close professional monitoring when used in this group.


Q: Can Zaranta be used by children?

According to the official product information, Zaranta is indicated as an adjunct to diet for pediatric patients (children and adolescents) who have certain severe cholesterol disorders, such as Familial Hypercholesterolemia (FH). The regulatory documents specify use starting in early childhood (e.g., age 7 or 8) for these specific diagnoses.


Q: Is Zaranta known by any other name?

The active ingredient in Zaranta is rosuvastatin calcium. The drug may also be known by its original brand name, Crestor, or by generic Rosuvastatin products. They all share the same active substance.


Q: Does Zaranta interact with common pain relievers?

The official product information does not specifically list common non-prescription pain relievers (like ibuprofen or acetaminophen) as major drug interactions. It is important that a person's healthcare professional is aware of all concomitant medication use, including over-the-counter products.


Q: Are there any specific foods to avoid when taking Zaranta?

The medicine can be taken with or without food at any time of day, according to the official administration guidelines. Regulatory documents do not mandate any specific food restrictions beyond the standard advice for cholesterol-lowering diets.


Q: Can I drink alcohol in moderation while using Zaranta?

Official product information advises caution regarding alcohol use. Regulatory documents warn that consuming substantial quantities of alcohol can increase the risk of liver enzyme abnormalities while taking this medicine.


Q: Are there any serious, but rare, side effects associated with Zaranta?

Official safety documents report serious side effects, including muscle damage (rhabdomyolysis) and rare cases of fatal and non-fatal liver failure. The full prescribing information lists adverse events and their frequencies based on clinical trials and post-marketing experience.


Q: Do the side effects of Zaranta usually go away over time?

Regulatory information reports that some side effects, such as cognitive issues (confusion or memory loss), have been observed to be reversible upon discontinuation of the statin. The symptoms typically resolve over a variable period once the medication is stopped.


Q: Is it normal to feel a little dizzy after starting Zaranta?

Dizziness has been reported as an adverse reaction in the clinical trials supporting the use of the drug. Any person experiencing this or any other symptom is advised to seek the evaluation of a healthcare professional.


Q: Does Zaranta affect sleep or cause insomnia?

Insomnia (difficulty sleeping) is listed as an adverse reaction reported in clinical trials. Patients experiencing sleep disturbances or other changes are encouraged to communicate these with a healthcare professional.


Q: Is Zaranta safe to take with common vitamin supplements?

Official documentation specifically lists high-dose niacin (a B vitamin) as potentially increasing the risk of muscle problems when taken with Zaranta. A healthcare professional should be informed of all supplements being used.


Q: Can Zaranta be taken with over-the-counter cold and flu medicines?

The regulatory label does not specifically name general cold and flu medicines as contraindications. However, a person's healthcare professional should be informed of all concomitant medications and over-the-counter products.


Q: How is Zaranta different from the generic active ingredient?

Zaranta is a brand-name product. It contains the exact same active pharmaceutical ingredient, rosuvastatin calcium, as the generic versions. The primary difference lies in the manufacturer and the inactive ingredients (excipients) used to form the tablet.


Q: What happens when a person stops taking Zaranta?

Studies and official documents indicate that the beneficial cholesterol-lowering effects of this medication are reversed when the drug is discontinued. Without continuous use, cholesterol levels typically return to the higher pre-treatment baseline.


Q: Is Zaranta known to cause dependency or withdrawal symptoms?

Rosuvastatin is not classified as a controlled substance by regulatory agencies. The official product label does not list physiological dependency or withdrawal symptoms following discontinuation.


Q: What is the mechanism of action for Zaranta in simple terms?

Zaranta works primarily in the liver by blocking the action of an enzyme called HMG-CoA reductase. This enzyme is crucial for the liver to produce cholesterol. By blocking this enzyme, the medicine reduces the amount of 'bad cholesterol' (LDL-C) circulating in the bloodstream.


Q: Can Zaranta be taken by people with high blood pressure?

High blood pressure (hypertension) is not listed as a contraindication in the official label. Clinical trials used to evaluate the medication often include patients with common cardiovascular risk factors, such as hypertension.


Q: Does Zaranta affect your blood sugar levels?

Official safety information reports that increases in HbA1 c (a measure of average blood sugar control) and fasting serum glucose have been reported with statin medicines. There have also been reports of new-onset diabetes mellitus.


Q: Does Zaranta affect a person's ability to drive or operate machinery?

The official label does not explicitly state an impact on driving. Any potential side effects that affect concentration or coordination are relevant to discuss with a healthcare professional before operating machinery.


Q: How often do the side effects of Zaranta occur?

The official label provides frequency categories for side effects based on clinical trials (e.g., incidence ge 2%). Specific incidence rates for common issues like headache or nausea can be found in the full prescribing information.


Q: Can Zaranta cause stomach upset or nausea?

Yes, nausea and abdominal pain are specifically listed among the adverse reactions most frequently reported in clinical trials. Persistent or severe stomach upset is a symptom that a healthcare professional should be informed about.


Q: Is it true that Zaranta is a relatively new drug?

The active ingredient, rosuvastatin (under its original brand name), was first approved by the U.S. Food and Drug Administration (FDA) in August 2003. This indicates it is a well-established medication within the statin class.


Q: What are the long-term safety expectations for Zaranta?

Long-term data from large clinical studies confirm the benefits in reducing cardiovascular events. However, regulatory warnings address long-term risks such as new-onset diabetes and rare reports of immune-mediated muscle issues. Safety monitoring continues through post-marketing surveillance programs.


Q: What is the full list of ingredients in Zaranta?

The medication contains the active substance, rosuvastatin calcium, as well as a specific list of inactive ingredients, or excipients, used to form the tablet. The complete list of both active and inactive components is provided in the full prescribing information.


Q: Does Zaranta interact with herbal supplements like St. John's Wort?

Some regulatory product monographs suggest St. John's Wort may affect how the body metabolizes statins, which could potentially lower the medicine's effectiveness. It is important that a person's healthcare professional is informed about the use of all herbal supplements.


Q: What is the purpose of the Warnings section for Zaranta?

The Warnings and Precautions section is a requirement from regulatory bodies intended to alert healthcare professionals and patients to important safety information. This includes known and potential serious adverse events or conditions that require special monitoring or dose modification.


Q: How is the safety of Zaranta monitored after it is released?

Safety is continuously monitored through post-marketing surveillance programs, such as the FDA’s MedWatch program. These systems allow healthcare providers and the public to report any suspected adverse reactions or quality issues associated with the medication.


Q: Is Zaranta only available as a prescription drug?

Yes, Zaranta (rosuvastatin) is officially categorized as a Human Prescription Drug. It is only available to the public with a doctor's prescription.


Q: Does Zaranta require a special monitoring test while taking it?

Routine monitoring may include liver enzyme tests, which are performed before starting therapy and as clinically indicated thereafter. Additionally, monitoring of the International Normalized Ratio (INR) is required if the medicine is taken with certain blood thinners like warfarin.


Q: Can I take Zaranta if I have a history of allergies to medications?

Zaranta is strictly contraindicated in patients with a known hypersensitivity to its active substance (rosuvastatin) or any component of the formulation. The label does not forbid use based on a general history of allergy to other, unrelated medications.


Q: Does Zaranta have a risk of affecting mental health or mood?

Adverse reactions reported in the official label include post-marketing reports of cognitive impairment (such as confusion or memory loss). Some regulatory documents have also noted mood changes, like depression. Any changes in mood or cognition are relevant to discuss with a healthcare professional.

How should Zaranta be stored and disposed of?

How to Store and Dispose of Zaranta?

Official regulatory guidelines mandate specific conditions for storing and discarding Zaranta (rosuvastatin) to ensure its quality and safety.


Storage Requirements

Zaranta tablets must be stored at a Controlled Room Temperature, typically maintained between 20 C and 25 C. To protect the tablets from degradation, they must be kept in the original container and the container must remain tightly closed to prevent moisture exposure. Consistent with universal safety standards, the medicine must always be stored out of the reach of children.


Disposal Instructions

When disposing of unused or expired Zaranta, specific rules apply. The medication should not be flushed down a toilet or poured down a drain. Instead, regulatory authorities advise disposal in the household trash by mixing the tablets with an unappealing material, such as coffee grounds or kitty litter, and sealing the mixture in a plastic bag before discarding it, or by utilizing a recognized drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zaranta found in:

A-Z Index: